DK1438310T3 - Beta-carbolin-derivater som PTP-inhibitorer - Google Patents
Beta-carbolin-derivater som PTP-inhibitorerInfo
- Publication number
- DK1438310T3 DK1438310T3 DK02780494T DK02780494T DK1438310T3 DK 1438310 T3 DK1438310 T3 DK 1438310T3 DK 02780494 T DK02780494 T DK 02780494T DK 02780494 T DK02780494 T DK 02780494T DK 1438310 T3 DK1438310 T3 DK 1438310T3
- Authority
- DK
- Denmark
- Prior art keywords
- diseases
- inhibitors
- beta
- ptpases
- diabetes
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 title 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 4
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102000018997 Growth Hormone Human genes 0.000 abstract 2
- 108010051696 Growth Hormone Proteins 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000122 growth hormone Substances 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34612501P | 2001-10-19 | 2001-10-19 | |
| US34617601P | 2001-10-19 | 2001-10-19 | |
| PCT/US2002/033520 WO2003033496A1 (fr) | 2001-10-19 | 2002-10-18 | Derives de beta-carboline en tant qu'inhibiteurs de ptp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1438310T3 true DK1438310T3 (da) | 2007-03-26 |
Family
ID=26994711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02780494T DK1438310T3 (da) | 2001-10-19 | 2002-10-18 | Beta-carbolin-derivater som PTP-inhibitorer |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6933303B2 (fr) |
| EP (1) | EP1438310B1 (fr) |
| JP (1) | JP2005508968A (fr) |
| AT (1) | ATE348828T1 (fr) |
| DE (1) | DE60216952T2 (fr) |
| DK (1) | DK1438310T3 (fr) |
| ES (1) | ES2278064T3 (fr) |
| WO (1) | WO2003033496A1 (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL374971A1 (en) | 2002-08-09 | 2005-11-14 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
| PA8586801A1 (es) | 2002-10-31 | 2005-02-04 | Pfizer | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso |
| EP1590349A1 (fr) * | 2003-01-27 | 2005-11-02 | Pfizer Inc. | Inhibiteurs de vih-integrase, compositions pharmaceutiques et methodes d'utilisation desdits inhibiteurs |
| AU2004210711B2 (en) * | 2003-02-12 | 2010-07-08 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
| US20040186151A1 (en) * | 2003-02-12 | 2004-09-23 | Mjalli Adnan M.M. | Substituted azole derivatives as therapeutic agents |
| CN1832920A (zh) | 2003-08-08 | 2006-09-13 | 特兰斯泰克制药公司 | 芳基和杂芳基化合物,组合物及其使用方法 |
| WO2005014532A1 (fr) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Composes aryle et heteroaryle, compositions et procedes associes |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7141596B2 (en) | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
| WO2005063748A1 (fr) * | 2003-12-31 | 2005-07-14 | Council Of Scientific And Industrial Research | Tiruchenduramine, alcaloide guanidine derivee de $g(b)-carboline |
| AU2005206570A1 (en) * | 2004-01-23 | 2005-08-04 | Novartis Vaccines And Diagnostics, Inc. | Tetrahydrocarboline compounds as anticancer agents |
| AU2005214349B2 (en) * | 2004-02-12 | 2011-11-03 | Transtech Pharma, Inc. | Substituted azole derivatives, compositions, and methods of use |
| US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| EP1737461B1 (fr) * | 2004-03-15 | 2012-12-12 | PTC Therapeutics, Inc. | Derives de carboline utiles dans l'inhibition de l'angiogenese |
| US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
| US7626025B2 (en) | 2004-03-30 | 2009-12-01 | Council Of Scientific And Industrial Research | Beta-carboline derived guanidine alkaloids, tiruchenduramine |
| CA2564356A1 (fr) | 2004-04-26 | 2005-11-03 | Pfizer Inc. | Inhibiteurs de l'enzyme integrase du vih |
| DE602005002746T2 (de) | 2004-04-26 | 2008-02-07 | Pfizer Inc. | Inhibitoren des hiv-integrase-enzyms |
| TW200607502A (en) * | 2004-05-17 | 2006-03-01 | Tibotec Pharm Ltd | 6, 7, 8, 9-substituted 1-phenyl-1, 5-dihydro-pyrido[3, 2-b]indol-2-ones |
| WO2005121140A1 (fr) | 2004-06-09 | 2005-12-22 | Glaxo Group Limited | Derives de pyrrolopyridine |
| EA019385B1 (ru) | 2006-01-30 | 2014-03-31 | ТРАНСТЕК ФАРМА ЭлЭлСи | ЗАМЕЩЕННЫЕ ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ РТРазы |
| JP2010533712A (ja) * | 2007-07-19 | 2010-10-28 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗糖尿病化合物としてのベータカルボリン誘導体 |
| US20110015254A1 (en) * | 2008-03-25 | 2011-01-20 | Merck Serono Sa | PTPH1 Inhibitors for the Treatment of Alzheimer's Disease |
| CN102378574B (zh) | 2009-03-30 | 2013-11-20 | 转化技术制药公司 | 取代的偶氮蒽衍生物、药物组合物及其使用方法 |
| US8697662B2 (en) | 2009-05-27 | 2014-04-15 | Ptc Therapeutics, Inc. | Methods for treating Kaposi sarcoma |
| MX2011012517A (es) | 2009-05-27 | 2012-01-27 | Ptc Therapeutics Inc | Procesos para la preparacion de tetrahidro beta - carbolina sustituidas. |
| US9351964B2 (en) | 2009-05-27 | 2016-05-31 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
| US8703726B2 (en) | 2009-05-27 | 2014-04-22 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
| WO2010147663A1 (fr) * | 2009-06-16 | 2010-12-23 | Massechusetts Institute Of Technology | Procédés et compositions d'inhibition de la prolifération de cellules aneuploïdes |
| WO2011063223A1 (fr) * | 2009-11-20 | 2011-05-26 | Southern Research Institute | DÉRIVÉS DE TÉTRAHYDRO-β-CARBOLINE, LEUR SYNTHÈSE ET UTILISATION |
| WO2012127885A1 (fr) | 2011-03-18 | 2012-09-27 | 小野薬品工業株式会社 | Dérivé de tétrahydrocarboline |
| CN102391323B (zh) * | 2011-10-18 | 2013-09-25 | 首都医科大学 | 四氢-β-咔啉衍生物、其制备方法及其用途 |
| CN103159758B (zh) * | 2011-12-13 | 2015-08-05 | 首都医科大学 | (1S,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸、其合成、抗栓活性和作为抗血栓剂的应用 |
| US20150018369A1 (en) * | 2012-01-09 | 2015-01-15 | University Of Washington Through Its Center For Commercialization | Compositions and Methods for Treating Malignant Astrocytomas |
| CN105153277A (zh) * | 2014-06-11 | 2015-12-16 | 首都医科大学 | KE修饰的β-咔啉,其制备,纳米结构,活性和应用 |
| IL285318B (en) | 2016-04-01 | 2022-09-01 | Kalyra Pharmaceuticals Inc | Estrogen receptor modulators |
| CN109790136B (zh) | 2016-12-22 | 2024-01-12 | 广州华睿光电材料有限公司 | 含呋喃交联基团的聚合物及其应用 |
| WO2018130123A1 (fr) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | Composé pentacyclique utilisé en tant que régulateur sélectif du récepteur des œstrogènes et son utilisation |
| KR20200035292A (ko) | 2017-08-01 | 2020-04-02 | 피티씨 테라퓨틱스, 인크. | 혈액 암 치료에 사용하기 위한 dhodh 억제제 |
| BR112022002138A2 (pt) | 2019-08-06 | 2022-04-19 | Recurium Ip Holdings Llc | Moduladores do receptor de estrogênio para tratamento de mutantes |
| JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
| EP4573093A1 (fr) * | 2022-08-19 | 2025-06-25 | Olema Pharmaceuticals, Inc. | Dérivés 2,3,4,9-tétrahydro-1h-pyrido[3,4]indole utiles en tant que modulateurs des récepteurs éstrogéniques pour le traitement du cancer |
| CN119462646A (zh) * | 2024-11-07 | 2025-02-18 | 江苏科技大学 | 一种取代的四氢-β-咔啉衍生物、其合成方法及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244905A (en) * | 1990-08-31 | 1993-09-14 | Warner-Lambert Company | N-substituted cycloalkyl and polycycloalkyl polyhydro-β-carboline-phenylalanine- and phenethylamine derivatives |
| US6388076B1 (en) * | 1995-06-19 | 2002-05-14 | Ontogen Corporation | Protein tyrosine phosphatase-inhibiting compounds |
| US5770620A (en) * | 1995-06-19 | 1998-06-23 | Ontogen Corporation | Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors |
| KR20000005175A (ko) * | 1996-04-04 | 2000-01-25 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 테트라하이드로-베타-카르볼린 유도체의 항전이제로서의 용도 |
| EP1007042A4 (fr) | 1997-06-13 | 2001-07-04 | Sugen Inc | Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine |
| WO1999046244A1 (fr) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulateurs de proteine tyrosine phosphatases (ptpases) |
-
2002
- 2002-10-18 ES ES02780494T patent/ES2278064T3/es not_active Expired - Lifetime
- 2002-10-18 US US10/274,546 patent/US6933303B2/en not_active Expired - Fee Related
- 2002-10-18 AT AT02780494T patent/ATE348828T1/de not_active IP Right Cessation
- 2002-10-18 JP JP2003536235A patent/JP2005508968A/ja active Pending
- 2002-10-18 EP EP02780494A patent/EP1438310B1/fr not_active Expired - Lifetime
- 2002-10-18 WO PCT/US2002/033520 patent/WO2003033496A1/fr not_active Ceased
- 2002-10-18 DE DE60216952T patent/DE60216952T2/de not_active Expired - Fee Related
- 2002-10-18 DK DK02780494T patent/DK1438310T3/da active
-
2004
- 2004-12-15 US US11/012,636 patent/US20050096335A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1067128A1 (en) | 2005-04-01 |
| DE60216952D1 (de) | 2007-02-01 |
| ES2278064T3 (es) | 2007-08-01 |
| US20050096335A1 (en) | 2005-05-05 |
| WO2003033496A1 (fr) | 2003-04-24 |
| US20040014778A1 (en) | 2004-01-22 |
| EP1438310A1 (fr) | 2004-07-21 |
| EP1438310B1 (fr) | 2006-12-20 |
| JP2005508968A (ja) | 2005-04-07 |
| ATE348828T1 (de) | 2007-01-15 |
| DE60216952T2 (de) | 2007-07-05 |
| US6933303B2 (en) | 2005-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1438310T3 (da) | Beta-carbolin-derivater som PTP-inhibitorer | |
| EA200801372A1 (ru) | Способы получения замещенных пиримидинов | |
| TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
| MXPA06012613A (es) | Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer. | |
| WO2005046603A3 (fr) | Composes pyridiniques | |
| DE60219793D1 (de) | Methode zur behandlung von zytokinvermittelten erkrankungen | |
| YU37904A (sh) | Benzimidazoli kao korisni inhibitori proteinske kinaze | |
| DZ3265A1 (fr) | Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2 | |
| TN2009000128A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| UA83194C2 (ru) | Производные пиримидина и их применение как модуляторов св2 | |
| ATE301654T1 (de) | Naphthyridinderivate | |
| NO20043016L (no) | 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav | |
| DE60015508T2 (de) | C-16 ungesätigte fp-selektive prostaglandin analoge | |
| ATE367380T1 (de) | Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate | |
| WO2003087062A3 (fr) | Composes heterocycliques, procede de preparation de ces composes et compositions pharmaceutiques les contenant, et utilisations en medecine | |
| AU2003260436A1 (en) | Pyrimidine compounds | |
| EP1441724B8 (fr) | Methodes pouvant augmenter des concentrations en testosterone endogene | |
| MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
| WO2024023262A3 (fr) | Composés d'acide nucléique | |
| BRPI0415355A (pt) | triarilimidazóis | |
| ATE320255T1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
| EA200600115A1 (ru) | Производные 2-аминобензойной кислоты | |
| DE50308230D1 (de) | Pyrazoloisoquinolinenderivaten zur inhibierung von nfkappab-induzierende kinase | |
| DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen |